Drug Pricing Regulator To Soon Fix Ceiling Rates Of Stents
New Delhi: The National Pharmaceutical Pricing Authority or NPPA is working on fixing ceiling prices of stents as the government has notified it in the Drug Prices Control Order (DPCO), 2013.
The decision of the Department of Pharmaceuticals comes months after the Ministry of Health in July included stents in the National List of Essential Medicines.
"We are on the job. We will do it as soon as possible," Bhupendra Singh, chairman of national drug pricing regulator NPPA, told PTI.
The Department of Pharmaceuticals has in a notification put "bare metal stents and drug eluting stents (DES), which include metallic DES and bioresorbable vascular scaffold (BVS)/biodegradable stents", in the Schedule I of DPCO 2013.   Â
NPPA is requested to take further action urgently, a letter to the chairman stated.
As per DPCO 2013, "ceiling price(s) for the medicine(s) added in the first schedule shall be fixed as per the provisions of this order within a period of 60 days from the date of the notification".
Expressing disappointment over the government's decision, the Advanced Medical Technology Association (AdvaMed) said the move hinders the fundamental right of a patient to have access to advanced, clinically proven, patient condition-specific and high-quality devices.
To overlook this clinical and patient-centric need through preoccupation to 'price capping' is short-sighted, it added.
Putting all Drug Eluting Stents (DES) into one category undermines the progress made in innovative device development over the years, AdvaMed said.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
